Abstract:Certain genetic mutations lead to the development of cancer through unchecked cell growth and division. Cancer is typically treated through surgical resection, radiotherapy, and small-molecule chemotherapy. A relatively recent approach to cancer therapy involves the use of a natural process wherein small RNA molecules regulate gene expression in a pathway known as RNA interference (RNAi). RNA oligomers pair with a network of proteins to form an RNA-induced silencing complex, which inhibits the translation of mRNA into proteins, thereby controlling the expression of gene products. Synthetically produced RNA oligomers may be designed to target and silence specific oncogenes to provide cancer therapy. The primary challenges facing the use of the RNAi pathway for cancer therapy are the safe and efficacious delivery of RNA payloads and their release at pertinent sites within disease-causing cells. Nucleases are abundant in the bloodstream and intracellular environment, and therapeutic RNA sequences often require a suitable carrier to provide protection from degradation prior to reaching their site of action in the body. The use of metal core nanoparticles (NPs) serving as targeted delivery vehicles able to shield and direct RNA payloads to their intended destinations have recently gained favor. Biological barriers present in the body establish a size prerequisite for drug delivery vehicles; to overcome recognition by the body's immune system and to gain access to intracellular environments, drug carriers must be small (< 100 nm). Iron oxide and gold core NPs can be synthesized with a high degree of control to create uniform ultrasmall drug delivery vehicles capable of bypassing key biological barriers. While progress is being made in size control of liposomal and polymer NPs, such advances still lag in comparison to the exquisite tunability and time stability of size engineering achievable with metal core NPs at bulk scales. Further, unlike lipid- and viral-based transfection agents, the biodistribution of metal core NPs can be traced using noninvasive imaging techniques that capitalize on the interaction of electromagnetic radiation and the inorganic atoms at the core of the NPs. Finally, metal core NPs have been shown to match the transfection efficiency of conventional RNA-delivery vehicles while also providing less immunogenicity and minimal side effects through the addition of tumor-targeting ligands on their surface. This Account reviews recent advances in the use of iron oxide and gold NPs for RNAi therapy. An overview of the different types of RNA-based therapies is provided along with a discussion of the advantages and current limitations of the technique. We highlight design considerations for the use of iron oxide and gold NP carriers in RNAi, including a discussion of the importance of size and its role in traversing biological barriers, NP surface modifications required for targeted delivery and RNA payload release, and auxiliary properties supporting imaging functionality for treatment monitoring. Applications of NPs for combination therapies including the pairing of RNAi with chemotherapy, photothermal therapy, immunotherapy, and radiotherapy are explored through examples. Finally, future perspectives are provided with a focus on the current limitations and the potential for clinical translation of iron oxide and gold NPs in RNAi therapy.

The application of nanoparticles in delivering small RNAs for cancer therapy

RNA Cancer Nanomedicine: Nanotechnology-Mediated RNA Therapy.

Nano-based delivery of RNAi in cancer therapy

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Recent advances in targeted gene silencing and cancer therapy by nanoparticle-based delivery systems

Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology

Recent Advances in Sirna Delivery for Cancer Therapy Using Smart Nanocarriers

Enhancing Chemotherapy by RNA Interference

Recent Advances in RNA-Targeted Cancer Therapy

Small Interfering RNA-based Molecular Therapy of Cancers

Efficient nanocarriers of siRNA therapeutics for cancer treatment

Nanostructured lipid carriers for MicroRNA delivery in tumor gene therapy

Progress in the Tumor Environment (Tme)-Responsive Nanocarriers for in Vivo Sirna Delivery

Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics

Theranostic Nanoparticles for RNA-Based Cancer Treatment

Powering up the molecular therapy of RNA interference by novel nanoparticles (vol 4, pg 1051, 2016)

A novel strategy for cancer gene therapy: RNAi

RNA Nanotechnology-Mediated Cancer Immunotherapy

Noncoding RNA for Cancer Gene Therapy.

Tumor-targeted RNA-interference: Functional Non-Viral Nanovectors.

Tumor-targeted Nano-Delivery System of Therapeutic RNA